Z-LEHD-fmk Options
MI-CP151 was a phase 1b randomised, double-blind, placebo managed, dose-escalation, multicentre review to evaluate various intravenous doses of sifalimumab, in Grownup sufferers with dermatomyositis or polymyositis (NCT00533091). Main demo aims had been To guage the safety and tolerability of sifalimumab in dermatomyositis or polymyositis sufferers